ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد ایتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Postpartum contraception: Counseling and methods

Postpartum contraception: Counseling and methods
Authors:
Sarita Sonalkar, MD, MPH
Sheila K Mody, MD, MPH
Section Editor:
Courtney A Schreiber, MD, MPH
Deputy Editor:
Kristen Eckler, MD, FACOG
Literature review current through: Jul 2022. | This topic last updated: Aug 15, 2022.

INTRODUCTION — The postpartum period is an ideal time to access contraception services, as patients are known to not be pregnant, they may be motivated to initiate contraception, and are under the care of clinicians with the appropriate expertise. Counseling involves understanding a patient's wishes regarding future pregnancy, their preferences regarding contraceptive options, and the characteristics and attributes of the contraceptive methods themselves. Additional medical considerations include timing of contraceptive start after delivery, medical comorbidities, and breastfeeding status.

This topic will review the available data and guidelines surrounding counseling patients about contraceptive selection and initiation in the postpartum period. Related information on contraceptive counseling and selection in general is presented separately. (See "Contraception: Counseling and selection".)

In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. However, we encourage the reader to consider the specific counseling and treatment needs of transgender and gender expansive individuals.

RESUMPTION OF OVULATION — In a systematic review of studies estimating the time to return to fertility in nonlactating postpartum people, the average time to first ovulation varied from 45 to 94 days postpartum, with the earliest reported ovulations at 25 and 27 days postpartum [1]. Although many first ovulations will be subfertile, some of the reported ovulations were estimated to be fertile, which highlights the importance of timely initiation of contraception postpartum. To address contraception and other acute postpartum needs in a timely way, postpartum follow-up within two to three weeks is advised [2]. Studies have documented wide variation in the percentage of people who attend the six-week postpartum visit (65 to 90 percent) [3]. In addition, a significant proportion of people, up to 51 percent in one study, will resume sexual activity before the six-week postpartum visit [1,4,5].

INTERPREGNANCY INTERVAL AND ROLE OF CONTRACEPTION ACCESS — Based on studies reporting adverse maternal, perinatal, and infant outcomes with shorter interpregnancy intervals (IPI; the interval between a live birth and conception of another pregnancy), the World Health Organization advises an interval of at least 24 months [6-9]. Similarly, the American College of Obstetricians and Gynecologists advises that patients should be counseled to avoid IPIs shorter than six months and be counseled about the risks and benefits of repeat pregnancy sooner than 18 months [2]. Adverse outcomes with short IPIs have been reported in both low- and high-resource settings, although data from studies in higher resource settings reported weaker associations between adverse outcomes and IPIs greater than six months as compared with intervals less than six months [7]. Despite these recommendations, international estimates of the unmet need for postpartum contraception are as high as 62 percent in the first year following childbirth [10-12]. (See "Interpregnancy interval: Optimizing time between pregnancies".)

From a public health perspective, IPI is clearly associated with the effectiveness of the postpartum contraceptive method; patients who use less effective methods are more likely to have shorter IPIs [13-15]. Conversely, initiation of one of the most effective contraceptives after delivery, including permanent contraception and long-acting reversible contraception (LARC), is associated with an 80 percent lower hazard of having a repeat delivery within 27 months compared with patients who did not initiate contraception [13]. Further, health policies that mandate insurance coverage of postpartum LARC are associated with increased rates of LARC usage and a subsequent decrease in short-interval births among adult and adolescent patients [16,17].

However, intent alone is ineffective if the contraceptive method is not available to the patient because of issues related to cost, staff education and training, or logistics. For example, patients who are unable to receive a desired postpartum permanent contraception during their birth hospitalization are at higher risk of pregnancy within one year compared with patients who do not request postpartum permanent contraception at all [18]. Internationally, the lactational amenorrhea method of contraception is often emphasized given its high initial efficacy and low risk [19] (see 'Other' below). However, this method is temporary, and patients may not visit a care provider during a time when a transition to another method is indicated. Thus, we advise that clinicians prioritize educating patients about birth spacing and patient-appropriate postpartum contraceptive options, ensuring method access prior to discharge, and arranging timely postpartum follow-up.

OUR APPROACH TO COUNSELING — For counseling patients about contraception, we use a patient-centered, shared decision-making model. Shared decision making is "a collaborative process that allows patients and their clinicians to make health care decisions together, taking into account the best scientific evidence available, as well as the patient's values and preferences… this process provides patients with the support they need to make the best individualized care decisions" [20]. Decisions about birth spacing are informed by multiple factors, including desired family size, beliefs about and access to contraception, and maternal age. Furthermore, the postpartum period is a clinically dynamic time, in which method eligibility may change based on venous thromboembolism (VTE) risk, breastfeeding status, and medical comorbidities. Patients often have a clear plan for postpartum contraception if counseling is done during the prenatal period, which then allows clinicians to ensure the desired method is available after delivery. Helping clinicians comprehensively, meaningfully, and accurately counsel postpartum patients regarding family planning is an important step in decreasing unmet need for postpartum family planning. Keeping system factors in mind during counseling is also important. For example, some patients may be insured for a limited time after delivery, and certain hospital systems may restrict access to contraceptive methods due to religious restrictions [21]. As patients do not necessarily fully understand system barriers, clinicians may need to advocate on their behalf and bridge gaps for patients who desire access to postpartum contraception [21,22].

We take the following approach, ideally starting during prenatal care, with portions repeated as needed (algorithm 1):

Discuss their reproductive life plan – Eliciting a discussion of a person's reproductive life plan is a natural start to counseling regarding postpartum contraception. This conversation should include questions about desire for, and timing of, any future pregnancies and should begin during prenatal care. We start a discussion about postpartum contraception broadly by first asking patients what their ideal family size might be. More specifically, clinicians can ask, "After you deliver, are you interested in having more children?" If they would like to have additional children, a follow-up question can be, "When do you think that might be?" [23]. This moment in the conversation may be appropriate for discussing health benefits of birth spacing, taking into account individual circumstances such as desired family size, personal values about birth spacing, and maternal age to guide creation of a reproductive health plan that is based on patient values as well as evidence-based recommendations (table 1) [6-9,24]. This can then lead to a discussion about whether a patient would like to actively prevent pregnancy after delivery. (See "Interpregnancy interval: Optimizing time between pregnancies".)

The choice of contraception is ultimately made by the patient. Detailed discussions of contraceptive efficacy and the general approach to method selection are presented separately. (See "Contraception: Counseling and selection".)

Discuss contraceptive characteristics – Once the patient's desire for additional children and subsequent birth spacing has been established, we determine the contraceptive characteristics that she values most at that time. We ask, "What is most important to you in a contraceptive method?" [20]. Attributes that patients may value in contraceptive methods include efficacy (figure 1), convenience (both in obtaining and using the method), cost, the ability to control whether to use the method, effect on uterine bleeding [25], and compatibility with breastfeeding. The ensuing conversation then starts with a discussion of the methods with the patient's most valued characteristic(s). For example, if a patient does not desire more children and values efficacy, then highly effective methods (ie, permanent or long-acting) would be discussed first and in detail. Even for patients with a clear contraceptive preference, all methods should be mentioned at least briefly to ensure the patient is fully aware of their options.

Review medical issues or comorbidities – In the first six weeks postpartum, multiple dynamic medical factors inform contraceptive method selection, particularly the elevated risk of VTE. With the exception of estrogen-containing methods, the Centers for Disease Control and Prevention (CDC) US Medical Eligibility Criteria (MEC) table classifies all methods immediately after delivery as either a category 1 or 2 [26,27]. The categories are defined as either no restriction (category 1) or the advantages of using the method generally outweigh the theoretical or proven risks (category 2). Due to the importance of breastfeeding in low-resource settings and the scarcity of high-quality data on the effect of hormonal contraception on breastfeeding outcomes [28,29], the World Health Organization (WHO) contraceptive eligibility criteria advise delaying progestin-only injectable methods to six weeks postpartum and estrogen-progestin combined methods to six months postpartum for breastfeeding patients [27]. The WHO guidelines, which are meant to apply to a wide range of settings and resources, are interpreted below. (See 'Impact of contraception on breastfeeding' below.)

Discuss plans for breastfeeding – When counseling patients regarding the interaction of contraception, particularly hormonal contraception, and lactation, it is paramount to develop a collaborative model with obstetric clinicians, pediatricians, and lactation consultants, as data are sparse in this area and messaging to patients should be consistent. Furthermore, given that high-quality data are limited, it is important to avoid "bedside advocacy," in which public health messages are conveyed that primarily reflect the priorities of the clinician [30]. Instead, we advise adopting a patient-centered, shared decision-making model, in which providers elicit patient priorities and tailor their recommendations to those priorities (table 1). All contraceptives are considered compatible with breastfeeding. (See 'Impact of contraception on breastfeeding' below.)

METHODS

Permanent contraception — Permanent contraception for either the female or male partner is an option for patients who do not desire future pregnancy. Efficacy rates are greater than 99 percent (figure 1).

Female – Postpartum permanent contraception may be performed via bilateral partial salpingectomy or bilateral complete salpingectomy. After vaginal delivery, partial salpingectomy can be performed via infraumbilical mini-laparotomy, preferably within 24 to 48 hours but up to six days postpartum, or at the time of cesarean delivery. At cesarean delivery, bilateral complete salpingectomy (to reduce the risk of high-grade serous ovarian cancer) or partial salpingectomy can be performed. However, studies report that one-third to one-half of patients who desire postpartum permanent contraception do not receive their desired procedure; risk factors for unfulfilled permanent contraception include elevated body mass index, time of delivery, and vaginal rather than cesarean delivery [18,31,32]. Deferral of desired permanent contraception after this time period results in high rates of unwanted pregnancy, up to 47 percent, within the first postpartum year, which is an issue for patients who deliver at hospitals with restrictive contraception policies [18,33,34]. For patients whose desired permanent contraception is unable to be performed during the birth admission, we offer other highly effective contraceptive methods and schedule the patient for subsequent interval laparoscopic permanent contraception. (See "Postpartum permanent contraception: Procedures".)

Counseling regarding postpartum female permanent contraception should ideally begin during the antenatal period. Shared decision making and patient-centered counseling is particularly important in preparation for permanent contraception; nonconsensual permanent contraception has been documented in the United States and other countries and has involved patients who are intellectually disabled, insured through federal funding, incarcerated, members of underrepresented groups, with chronic disease, or disenfranchised in some way [35-39]. Cases in the United States resulted in court-mandated waiting periods for permanent contraception in patients with public insurance, although these restrictions have since been criticized for creating unnecessary barriers to permanent contraception access for this population [40].

Given these restrictions, a discussion about permanent contraception should not be deferred to the end of pregnancy. Consent for permanent contraception should be considered as a process of delivering information, confirming voluntariness, and confirming understanding of information and, as such, should be delivered in comprehensible language with the use of an interpreter if needed [41]. A patient's decision regarding whether to proceed with permanent contraception should be reaffirmed during the delivery admission prior to surgery, as their wishes may have changed during their pregnancy. (See "Overview of female permanent contraception", section on 'Counseling'.)

General information on female permanent contraception, United States mandated waiting periods, and techniques of postpartum permanent contraception are reviewed elsewhere.

(See "Overview of female permanent contraception".)

(See "Overview of female permanent contraception", section on 'United States regulatory issues'.)

(See "Postpartum permanent contraception: Procedures".)

Male – Vasectomy is a surgical procedure that provides permanent contraception for males. Advantages include that it is highly effective (less than 1 percent failure rate), a minimally invasive outpatient procedure, and widely available. Vasectomy is presented in detail separately. (See "Vasectomy".)

Progestin-only implants — Etonogestrel (commercial name Nexplanon) and levonorgestrel (LNG) implants (commercial names Jadelle and Sino-implant [II]) can be safely inserted at any time after delivery, as the advantages generally outweigh the theoretical or proven risks [26,27].

Details regarding the contraceptive implant in general, insertion, and the effect of the implant on lactation are described separately.

(See "Etonogestrel contraceptive implant".)

(See "Etonogestrel contraceptive implant", section on 'Insertion procedure'.)

Intrauterine devices — Both copper and LNG-releasing intrauterine devices (IUDs) can be inserted after delivery.

Device types and candidates — IUD device types, candidates and device selection, techniques for insertion and removal, and management of side effects and complications are described separately.

(See "Intrauterine contraception: Background and device types".)

(See "Intrauterine contraception: Candidates and device selection".)

(See "Intrauterine contraception: Insertion and removal".)

(See "Intrauterine contraception: Management of side effects and complications".)

Options for timing of insertion after delivery — For patients who desire an IUD after delivery, explicit counseling should center on timing of IUD insertion. Although nomenclature to describe timing of IUD insertion in the postpartum period can vary, we use the Society of Family Planning definitions to describe IUD insertion after delivery including [42]:

Postplacental (immediate postpartum) – Defined as within 10 minutes of delivery of the placenta

Early postpartum insertion – Defined as IUD insertion >10 minutes to one week postpartum

Delayed postpartum – IUD insertion one week through six to eight weeks after delivery

Interval – IUD insertion unrelated to timing of delivery (ie, beyond the postpartum period)

Risks (eg, expulsion and perforation) and benefits (eg, effectiveness) vary by timing of IUD placement after delivery. Although some outcome variables differ by timing of insertion, overall, IUD insertion at all time points after delivery is safe [42-44], with very low incidence of perforation [45], infection [46-49], and/or heavy vaginal bleeding [50,51]. Postplacental IUD placement is contraindicated in patients with chorioamnionitis, endometritis, or active postpartum hemorrhage [42].

Facilitating postpartum IUD insertion

Standardized counseling script embedded in the electronic health record – In our practice, we use an electronic medical record-based script to guide counseling regarding postpartum IUD placement, in which providers are prompted to review the differential risks of postplacental and delayed postpartum IUD placement including expulsion, malposition, and missing strings; that follow-up is recommended after postplacental insertion to assess for positional abnormalities; and that the advantage of postplacental IUD insertion is maximized for patients who may not be able to return for delayed postpartum insertion or who wish to avoid a separate procedure. Although predictors for nonattendance to follow-up have been described [52], these predictors cannot be used on an individual level to prioritize access to postplacental IUDs, particularly because follow-up after postplacental IUD placement is important in the recognition of complications of this contraceptive method.

Early postpartum evaluation – We advise removing potential barriers to a two- to three-week postpartum visit [2,53] and early ultrasound evaluation for patients who receive a postplacental IUD, enabling sufficient time for confirmation of IUD position if needed, prior to the potential for return to fertility. Furthermore, in settings in which patients have insurance coverage for a finite number of weeks after delivery, early recognition of IUD positional abnormalities allows for clinical management during the time of coverage.

Health center support for postpartum contraception – Given the public health benefit of access to immediate postpartum long-acting reversible contraceptives (LARC), health systems should work to provide this service to patients. However, logistical, financial, and educational barriers may restrict the development of these programs at a departmental level. The American College of Obstetricians and Gynecologists publishes and collates a variety of resources to aid in the development and sustainability of immediate postpartum LARC programs.

Issues related to postpartum IUD insertion

Expulsion — Expulsion rates appear to differ by timing of IUD placement, mode of delivery, device type, and duration of follow-up studied. Absolute expulsion rates for postpartum IUD insertion range from 10 to 40 percent, compared with 3 to 10 percent for non-postpartum patients [46,54-60]. Two different meta-analyses of 48 studies that pooled counts of postpartum IUD placements and expulsions and adjusted for IUD type, delivery method, study region, study quality, and length of follow-up reported [54,61]:

Early versus interval insertion – Risk of expulsion was six to seven times higher for immediate and delayed insertion compared with interval insertion (adjusted risk ratio [RR] 7.63, 95% CI 4.30-13.51 and RR 6.17, 95% CI 3.19-11.93, respectively) [54]. Similarly, a prospective cohort study including over 320,000 patients given birth by either route between 2001 and 2018 reported the highest five-year cumulative IUD expulsion rates for those inserted between 0 to 3 days postpartum (10.73 percent, 95% CI 9.12-12.61) and lowest rates for IUDs inserted more than 6 but less than 14 weeks following birth (3.18 percent, 95% CI 2.95-3.42) [62].

Vaginal versus cesarean birth – Vaginal birth conferred a fivefold increased risk of expulsion compared with cesarean birth (adjusted RR 5.19, 95% CI 3.85-6.99).

LNG versus copper IUD – Risk of expulsion at less than four weeks postpartum was nearly double for the LNG-releasing IUD compared with the copper IUD (adjusted RR 1.91, 95% CI 1.50-2.43).

Among immediate postplacental placements following vaginal birth, LNGIUDs have nearly twice the risk of expulsion of copper IUDs (adjusted RR 1.90, 95% CI 1.36-2.65).

Using ultrasound to guide postpartum IUD placement following vaginal birth does not appear to lower IUD expulsion rates [46,63]. In our practice, we advise patients who have had postplacental insertion of an IUD to undergo ultrasound evaluation of IUD position at four to six weeks postpartum.

Uterine perforation — Available studies suggest that the absolute risk of uterine perforation with postplacental IUD insertion is low. Some studies suggest perforation rates are no greater postpartum than with insertion more than six months following birth [42,45,64].

Low risk of uterine perforation

A retrospective cohort study including nearly 25,000 patients receiving a postpartum IUD, absolute perforation rates were low although perforation was slightly more likely with delayed versus interval insertion (perforation after IUD insertion 4 to 8 weeks postpartum = 0.78 percent versus perforation after IUD placement 9 to 36 weeks postpartum = 0.46 percent, adjusted odds ratio 1.92, 95% ci 1.28-2.89) [65].

In a trial of 201 participants randomly assigned to IUD placement at three or six weeks postpartum (ie, delayed postpartum insertion), no complete expulsions or perforations occurred [66].

Data from the Assessment of Perforation and Expulsion of Intrauterine Devices (APEX IUD) study included in the Mirena IUD labeling indicate that risks of uterine perforation are highest in those with IUD insertion less than or equal to six weeks postpartum, with higher risk in breastfeeding patients. Rate of perforation was 11 in 1000 in those who were breastfeeding and between four days and six weeks postpartum. Perforation in the early postpartum period was reported to be 4 in 1000 in breastfeeding patients and 0 in 1000 in nonbreastfeeding patients [67].

Impact of lactation – Beyond six weeks postpartum, IUD perforation rates appear to be somewhat higher in breastfeeding as compared with nonbreastfeeding participants, although overall perforation rates in both populations are exceedingly low (less than 1 percent in both groups) [68,69]. Risk of perforation is not considered a reason to defer IUD insertion in breastfeeding patients.

Diagnosis and management of uterine perforation are presented elsewhere. (See "Intrauterine contraception: Management of side effects and complications".)

Abnormal IUD position — Postplacental IUD placement appears to be associated with more positional abnormalities compared with delayed or interval placement. In a prospective cohort study of 200 participants receiving the Copper T380A IUD immediately after vaginal birth, 15 percent were malpositioned (defined as rotated or away from the fundus but not partially expelled) [64]. Data on proportion of IUDs that are malpositioned after delayed postpartum or interval placement are scant, although "device-related" reasons for discontinuation (most of which were not malpositions) occurred in only 0.12 to 0.24 per 1000 participants by one year in a large randomized controlled trial of the LNG versus copper IUD [70]. In a case-control study, malpositioning after interval IUD placement was more likely to be identified in participants with suspected adenomyosis and less likely to be reported in participants with a prior vaginal birth and with private insurance [71]. Physiologic reasons for these risk factors are unclear.

However, the clinical significance of abnormal IUD position is unknown. Prior research shows that greater distance of copper from the cornua decreases effectiveness of a copper IUD, suggesting that IUD malposition may decrease effectiveness as well [72,73]. The proportion of patients who experience pain or bleeding abnormalities with IUD malposition is not known [72,73]. Given the paucity of data in this area, we recommend offering IUD replacement to patients experiencing this outcome, especially those patients experiencing discomfort.

IUD strings — IUD strings are folded into the uterus and are unable to be visualized on speculum examination in nearly one-quarter of patients who have postplacental placement after vaginal birth [64,74]. Presence of IUD strings is a poor test to assess correct position of an IUD placed after placental delivery; conversely, absence of IUD strings is a poor test to predict abnormal IUD positioning. The sensitivity and specificity of a string check as a test for IUD position are 36.2 and 84.5 percent in patients who have a postplacental IUD after vaginal birth [64].

Patients who desire postplacental IUD insertion should be counseled regarding the potential increased risk of absent strings. In addition, patients may be bothered by long strings resulting from uterine involution after postplacental IUD placement. One study comparing postplacental with delayed LNG IUD insertion reported that 17 percent of patients with a postplacental IUD had an unscheduled clinic visit for IUD string trimming; unscheduled visits for string trimming were not reported for patients in the delayed insertion group [46]. Given the lower risk of expulsion of an IUD after cesarean birth but the higher risk of nonvisible strings, string check is likely an even poorer test to assess IUD position after cesarean birth [75].

IUD continuation rate — Despite the increased risk of expulsion, perforation, and positional abnormalities after postplacental IUD insertion, the odds of using an IUD six months after delivery is twice as high for patients who receive a postplacental IUD as compared with interval insertion (odds ratio 2.04, 95% CI 1.01-4.09) [3]. A different study reported 81 percent of patients who received a postplacental copper IUD were still using it six months after delivery despite the complications [64]. This relatively high retention rate appears to translate into higher contraceptive efficacy of intended postplacental IUD placement compared with intended delayed postpartum IUD placement, as indicated by a decision analysis study [3]. Despite higher rates of expulsion, intended postplacental IUD insertion is more effective in preventing pregnancy at one year than intended delayed insertion.

The primary factor influencing variation in estimates of intended IUD effectiveness is the proportion of patients who return for a postpartum visit. A practice would need to have postpartum follow-up rates of 90 percent or greater in order for intended delayed postpartum IUD insertion to be a more effective method of contraception than intended postplacental IUD placement. On the other hand, once the IUD is placed, a delayed postpartum IUD is more effective than a postplacental IUD, due to the lower expulsion rate. Thus, public health and individual-level benefits of postplacental IUD placement may be in conflict, and it is essential to clearly educate patients on the risks and benefits of both timings of IUD placement [3].

Short-acting hormonal contraception — Short-acting reversible hormonal contraception includes progestin injections and oral pills as well as combined estrogen-progestin products (oral pills, patch, vaginal ring). These are considered highly effective methods of contraception (figure 1). While progestin-only methods can be started any time in the postpartum period, combined hormonal contraception (CHC) should not be initiated earlier than 21 days postpartum for any patient because of the increased risk of venous thromboembolism (VTE) [26].

Advantages of these methods include relative ease of use, wide access, relatively low upfront cost, and noncontraceptive benefits. As discussed in detail below, the World Health Organization's (WHO) contraceptive eligibility criteria advise waiting longer before starting hormonal contraceptives in lactating patients compared with the Centers for Disease Control and Prevention (CDC) table. In our practice, we counsel patients that the advantages of immediate initiation of progestin-only methods are believed to outweigh the theoretical risks. We delay initiation of CHC for at least 21 days postpartum for all patients because of the increased risk of VTE. (See 'Impact of contraception on breastfeeding' below and 'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period' below.)

Progestin-only injectable – This method, which can be administered during the birth admission, has the advantage of being a single injection that lasts 12 weeks. Postpartum depot medroxyprogesterone acetate (DMPA) can therefore bridge to an outpatient postpartum visit, at which time a patient may switch methods or continue DMPA, as desired. DMPA is available in both intramuscular and subcutaneous forms (patients may self-inject subcutaneous DMPA). Some clinicians and practitioners have raised concerns about a link between DMPA and postpartum depression, but studies have reported conflicting results. A clear link between DMPA and postpartum depression has not been proven or excluded [76,77]. While immediate use of DMPA has been associated with a small increased risk of VTE, the overall incidence remains low [78]. (See 'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period' below.)

Patient selection, risks and benefits, and administration of DMPA are presented in separate discussions.

(See "Depot medroxyprogesterone acetate (DMPA): Formulations, patient selection and drug administration".)

(See "Depot medroxyprogesterone acetate (DMPA): Efficacy, side effects, metabolic impact, and benefits".)

Progestin-only pills – Progestin-only pills (POPs) can be initiated at any time after delivery. Two POPs are available: norethindrone 0.35 mg, taken at the same dose daily; and drospirenone 4mg, taken in a 24-4 regimen (24 active pills followed by 4 placebo pills). The efficacy of norethindrone is likely lower than CHCs due to the need to take them at nearly the same time every day [79]. However, drosperinone, a newer POP, reliably inhibits ovulation, even in the setting of skipped pills.

In a retrospective cohort study, patients who had a short interpregnancy interval were most likely (fivefold increased risk) to have been prescribed a norethindrone progestin pill compared with any other reversible method, including no method at all [79]. The reason for this finding is unclear, but it may be indicative of low continuation rates for POPs in the postpartum period. Patients who prefer oral contraceptive pills may use POPs until 21 days if they have no risk factors for VTE, or until 42 days if they do have risk factors for VTE; then, they may switch to combined oral contraception if desired [26]. As discussed below, the WHO and CDC have differing recommendations regarding the timing of initiation for both progestin-only and estrogen-containing methods [26,27]. (See 'Impact of contraception on breastfeeding' below.)

Information on candidates, use, and side effects of progestin-only pills is reviewed in detail elsewhere. (See "Progestin-only pills (POPs) for contraception".)

Combined hormonal contraception (pills, patch, and vaginal ring) – CHCs include both an estrogen and a progestin. Formulations include pills, patch, and vaginal rings. CHC is not recommended until three to six weeks postpartum due to the effect of estrogen on VTE risk. (See 'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period' below.)

Detailed discussions of candidate selection, efficacy, and risks and benefits of each of the CHC methods are available separately.

(See "Combined estrogen-progestin oral contraceptives: Patient selection, counseling, and use".)

(See "Combined estrogen-progestin contraception: Side effects and health concerns".)

(See "Contraception: Transdermal contraceptive patches".)

(See "Contraception: Hormonal contraceptive vaginal rings".)

Other

Lactational amenorrhea method – The lactational amenorrhea method (LAM) is defined as the educated use of breastfeeding as a contraceptive method while amenorrheic and not using supplementary feeding or breast pumps for up to six months after delivery. It is thought that infant suckling results in a reduction of pulsatile secretion of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), which in turn suppresses ovarian activity. The exact mechanism by which the suckling stimulus affects GnRH pulsatile secretion remains unknown [19,80].

Life table pregnancy rates for LAM at six months range from 0.45 to 7.5 percent (ie, 4.5 to 75 unintended pregnancies per 1000 patients exclusively using this method) in controlled and uncontrolled studies [19]. Studies have not found clear differences in pregnancy rates between patients using LAM specifically as a contraceptive method and those who are fully breastfeeding and amenorrheic but not reporting use of any method. Thus, there is no evidence that LAM as a contraceptive method delays the recurrence of menstruation any more than exclusive breastfeeding.

Promotional and training materials for LAM often advise transitioning to other contraceptive methods as soon as supplemental feeding or menstruation starts, or once the baby is older than six months. However, 20 to 56 percent of fully nursing people are not amenorrheic at six months, and many will stop exclusively breastfeeding prior to six months [19]. Given the variable rates of patient follow-up after delivery, it seems prudent to use the first months following delivery to promote and support patients in exclusive breastfeeding for infant health, while also providing highly effective contraceptive methods as desired within the first few weeks postpartum.

Pericoital methods – Pericoital methods of contraception, including diaphragms and cervical caps, are not to be used for the first six weeks postpartum, as the uterus is still undergoing involution at this time. Spermicides, the vaginal pH regulator [81], and the contraceptive sponge may be used without restriction in the first weeks postpartum, although vaginal irritation is common with these methods. (See "Pericoital contraception: Diaphragm, cervical cap, spermicides, and sponge".)

Barrier methods – In the first six weeks after delivery, both female and male condoms can be used for pregnancy prevention without restriction. (See "Internal (formerly female) condoms" and "External (formerly male) condoms".)

Emergency contraception — All patients who wish to avoid pregnancy should be aware of emergency contraceptive (EC) methods and when and how to access them. The copper IUD, levonorgestrel 52 mg IUDs, oral LNG, and oral ulipristal acetate (UPA) are safe for use in postpartum and breastfeeding patients [82]. However, breastfeeding is not advised for 24 hours after taking UPA. Patients who are breastfeeding and require UPA are counseled to pump or express, and then discard, their breastmilk for 24 hours after taking UPA. Ethinyl estradiol plus LNG (Yuzpe method) should be avoided in the first three to six weeks postpartum due to possible increased risks of VTE with this method. Use of a copper IUD for EC is safe for postpartum patients [82].

EC options, risks and benefits, and use are presented in detail separately. (See "Emergency contraception".)

IMPACT OF CONTRACEPTION ON BREASTFEEDING

Copper intrauterine device — The copper intrauterine device (IUD) does not affect milk supply or breastfeeding [68].

Issues surrounding hormonal contraception during breastfeeding

Concerns — Concerns have been raised that exogenous hormones could impact lactogenesis and thereby affect breastfeeding performance (eg, breastfeeding frequency, proportion breastfeeding at different time periods), infant milk intake, or infant health outcomes (such as weight and height). Progesterone withdrawal after delivery initiates production of copious milk. The action of infant suckling and removal of milk increases prolactin levels, which causes alveolar cells to produce milk. This combination of suckling and elevated prolactin then prompts oxytocin levels to increase and causes alveolar contractions to release milk into the ductal system.

However, concerns about the impact of hormonal contraception on lactation and breastfeeding must be balanced against the method benefits (both contraceptive and noncontraceptive) and the potential harms to the infant if breastfeeding is interrupted. As an example, for people in low-resource regions, the World Health Organization (WHO) advises exclusive breastfeeding for the first six months of life to reduce the risk of infant diarrheal illness and respiratory infection [83]. In response to these variables and in recognition of the medical importance of breastfeeding (particularly in low-resource regions), the paucity of high-quality evidence on the effects of hormonal contraception on breastfeeding outcomes [28,29], and the varying populations, the WHO and the Centers for Disease Control and Prevention (CDC) have published differing opinions on the timing of initiation of hormonal contraception in postpartum patients [26,27]. The WHO contraceptive eligibility criteria advise delaying progestin-only injectable methods to six weeks postpartum and estrogen-progestin combined methods to six months postpartum, while the CDC table does not advise against any hormonal contraceptive method while breastfeeding, although use of combined hormonal contraception (CHC) is delayed for at least the first three weeks after delivery because of elevated risk of venous thromboembolism (VTE) [26,27]. (See 'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period' below.)

The data informing the WHO and CDC statements are presented in detail below for each method. In general, the available evidence does not support a significant or consistent effect of hormonal contraception on breastfeeding outcomes. Only small amounts of estrogen and progestins are transferred to the infant through breastmilk, and data have not suggested adverse health effects of these hormones on infants [29]. However, high-quality data are lacking, and most studies on hormonal contraception and breastfeeding have included low-risk people and those who have had success with breastfeeding prior children, or have not controlled for prior success with breastfeeding. Further research is needed on the effect of hormonal contraception on patients with preterm infants for whom breastfeeding provides additional benefits, or in patients who are primarily using breast pumps to express milk.

Progestin-only methods

Progestin-only implants – Neither the etonogestrel or levonorgestrel (LNG) contraceptive implants appear to have a negative effect on breastfeeding outcomes, although the available data are limited to observational studies or small trials [84,85]. In a trial including 24 participants who received either the contraceptive implant immediately after delivery or no contraceptive method, infant milk intake, rates of exclusive breastfeeding, and newborn weights were similar between the groups at six weeks postpartum [86]. Milk consumption was determined by having the participants ingest the stable isotope deuterium (D2O) on postpartum days 0 and 29, and then determining infant milk intake by measuring infant salivary D2O levels. A systematic review of cohort studies comparing postpartum participants using etonogestrel implants or the copper IUD did not show differences in infant growth or other infant health outcomes [28]. In a trial comparing immediate (within five days) or delayed (six to eight weeks postpartum) insertion of the LNG implant, change in infant weight from birth to six months, time to lactogenesis, and proportion of participants who were breastfeeding exclusively did not differ between groups [87].

In response to these data, both the WHO contraceptive eligibility criteria and CDC table agree that the advantages of progestin-only implants generally outweigh theoretical or proven risk and support immediate use of progestin-only implants in breastfeeding patients (although the timing of this label varies slightly between the groups) [26,27]. In our practice, we routinely offer contraceptive implants to patients prior to discharge from the hospital after delivery in order to ensure access to the method.

Progestin-releasing IUDs – Studies of the LNG IUD in people who are breastfeeding have generally reported minimal to no effect on breastfeeding outcomes, and the advantages of the LNG IUD are considered by the CDC's medical eligibility criteria and WHO to outweigh any theoretical or proven risks in those who are breastfeeding [26,84]. In a trial of 259 participants randomly assigned to immediate (postplacental) or delayed (4 to 12 weeks postpartum) insertion of an LNG IUD, no differences were reported for any breastfeeding, time to lactogenesis, exclusive breastfeeding at eight weeks, or any breastfeeding at six months postpartum [88]. While one study limitation may have been a noninferiority margin that could have masked a true difference in the primary outcome, exploratory outcomes of breastfeeding at six months were reassuring. Due to the paucity of data on expulsion of an IUD when inserted from 48 hours to four weeks after delivery, WHO contraceptive eligibility criteria, but not the CDC table, state that the theoretical or proven risks usually outweigh the advantages of using the method during this period; this restriction is unrelated to any potential effect on breastfeeding. In our practice, we offer LNG IUDs at any time in the postpartum period in accordance with CDC guidance and counsel regarding signs and symptoms of IUD expulsion. (See 'Expulsion' above.)

Progestin-only injectable – The effect of progestin-only injectable contraception on breastfeeding has been examined in clinical trials and observational studies, and most have reported either no change or improved breastfeeding outcomes for depot medroxyprogesterone acetate (DMPA) users and generally demonstrated no harmful effects on infant growth, health, or development [28]. However, citing a concern from animal studies that reported a possible effect of DMPA on the developing rat brain, the WHO contraceptive eligibility criteria advise delaying initiation of DMPA in those who are lactating until six weeks postpartum [27]. The WHO also includes a caveat in their guidance that recognizes the importance of DMPA in the immediate postpartum period in many settings where other methods are less accessible and thus supports DMPA use when that is the best option. By contrast, the CDC table states that immediate use of DMPA generally outweighs any proven or theoretical concerns and that it can be used without restriction in those who are breastfeeding more than 30 days postpartum [26]. In our practice, we offer DMPA at any time in the postpartum period, including immediately after delivery, in accordance with CDC guidance as we believe the benefits outweigh any theoretical risks.

Progestin-only pills – Both trial and observational data generally support the use of progestin-only pills (POPs) in the postpartum period [28,89,90]. One trial of nearly 130 participants reported no differences in breastfeeding continuation or supplementation at six months postpartum for participants using POPs compared with combined oral contraceptive pills [90]. In a systematic review of eight observational studies including those who started POPs in the first six weeks postpartum, POP users had either no difference or improved breastfeeding outcomes compared with nonusers; study outcomes included breastfeeding initiation, breastfeeding duration, or use of supplementation [28]. Both the WHO and the CDC agree that people who are breastfeeding less than six weeks postpartum can use POPs, as the benefits appear to outweigh the risks. Beyond six weeks, there are no restrictions [26,27]. In our practice, we offer POPs at any time during the postpartum period in accordance with CDC and WHO guidance.

Combined estrogen-progestin methods — In general, studies assessing the impact of CHCs (pills, patch, vaginal ring) on breastfeeding duration and success have reported inconsistent data. In a 2015 meta-analysis that included four trials of combined oral contraceptive pills, one trial reported a negative effect on breastfeeding duration while the other three trials did not assess this outcome [91]. Two trials reported lower breast milk volume for oral CHC users compared with placebo; one trial did not quantify results, and the other reported lower mean volumes that were unlikely to be clinically meaningful. In a trial performed after the meta-analysis that assessed participants who initiated their desired contraceptive method on postpartum day 42, infant breast milk intake and growth were similar between participants using hormonal and nonhormonal contraception [92].

The WHO contraceptive eligibility criteria advise delaying use of estrogen-containing methods until six months postpartum for those who are primarily breastfeeding because of the importance of breastfeeding on infant health in low-resource settings [27]. They advise people who desire CHCs to begin other progestin-only or nonhormonal methods until CHC is initiated. (See 'Impact of contraception on breastfeeding' above.)

As presented in the CDC contraceptive table, CHC should be avoided until at least 30 days postpartum due to the increased risk of VTE [26]. Breastfeeding people who do not have additional VTE risk factors may reasonably begin CHC at 30 days postpartum. However, breastfeeding people with additional VTE risk factors should delay CHC initiation until at least 42 days (six weeks) postpartum.

Consistent with CDC guidance, we avoid prescribing CHCs for the first three to six weeks postpartum due to increased risk of VTE in the postpartum period (timing of initiation varies based on VTE risk factors). After three to six weeks postpartum, breastfeeding is generally established, and we offer CHC to postpartum patients who are appropriate medical candidates consistent with the CDC medical eligibility criteria [26]. (See 'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period' below.)

Other — Pericoital and barrier methods of contraception do not impact milk supply or breastfeeding.

COUNSELING REGARDING VENOUS THROMBOEMBOLISM RISK AND HORMONAL CONTRACEPTION IN THE POSTPARTUM PERIOD — There are few studies evaluating the incidence of venous thromboembolism (VTE) in postpartum patients using combined hormonal contraceptives (CHCs) or progestin-only contraceptives. However, the risk of VTE associated with CHC use in healthy nonpregnant patients is three to seven times higher than in nonusers, and thus, use of CHCs for the initial three to six weeks postpartum is generally contraindicated [26,27,93]. Most evidence does not suggest an increase in odds for venous or arterial thromboembolic events with the use of progestin-only oral or implantable contraceptives. A database study comparing over 8300 individuals who received an etonogestrel implant during the delivery admission with unexposed postpartum individuals reported similar 30-day readmission rates for VTE for both groups (adjusted odds ratio 1.81, 95% CI 0.44-7.45) [94]. While several studies have reported an increased risk of VTE with the use of progestin-only injections, the absolute incidence remains low [78,95,96]. Both the World Health Organization and the Centers for Disease Control and Prevention advise that the data supporting immediate use of progestin-only contraception generally outweigh the risks, either established or theoretical [26,27].

Patients in the postpartum period have a higher risk of VTE compared with both nonpregnant, non-postpartum patients and pregnant patients. Normal hematologic changes in the postpartum period include increasing coagulation factors and fibrinogen, and decreasing natural anticoagulants protein S and adenomatous polyposis coli, which likely occur to prevent hemorrhage after delivery. A systematic review estimated that the risk of VTE is as much as five times higher during the postpartum period compared with pregnancy itself, and during the first six weeks postpartum, patients' risk of VTE increases 21- to 84-fold from baseline [93]. The systematic review further reported the incidence rate of VTE was 357.3 in week 1, decreased weekly through the first six postpartum weeks to 31.5, and then plateaued at 3.2 in postpartum weeks 7 to 12. (See "Maternal adaptations to pregnancy: Hematologic changes", section on 'Coagulation and fibrinolysis'.)

SPECIAL POPULATIONS

Adolescents – Selection of contraception for postpartum teens and young adults does not differ from that of older patients. Issues specific to adolescents are discussed separately. Access to long-acting reversible contraceptives, including implants and intrauterine devices, immediately after delivery has been shown to increase time to next pregnancy in adolescents and is an important public health intervention in this age group [55]. (See "Contraception: Issues specific to adolescents".)

Patients with depression and related disorders – Hormonal contraception, both estrogen-progestin and progestin-only methods, can be used by patients with depressive disorders (either preexisting or postpartum) [26,27]. There are no restrictions for this use of hormonal contraception in this population in both the Centers for Disease Control and Prevention (CDC) table and World Health Organization (WHO) contraceptive eligibility criteria.

In a systematic review that included 26 studies, no clear relationship was noted between progestin contraceptives and depression scores or incident diagnoses [97]. Some studies evaluating the effect on mood of depot medroxyprogesterone acetate (DMPA) in postpartum patients have suggested that injectable progestin-only contraception may increase depression scores temporarily in postpartum patients; however, data are not robust [76,98], and other studies have reported conflicting results [77]. We believe that the data are conflicting enough that providers should not restrict DMPA postpartum in those patients who desire it. Counseling on method risks should be comprehensive, and screening for postpartum depression should occur regardless of contraceptive method chosen.

Medical illness – Patients with comorbid medical conditions should be offered contraceptive methods in accordance with the WHO contraceptive eligibility criteria, or other relevant national guidance. Mobile applications are readily available for quick reference regarding patients' eligibility for contraceptive methods based on comorbid conditions, including patients with thromboembolic disease, hypertension, diabetes, headache, HIV infection, obesity, pelvic infection, and seizure disorders.

Patients taking other medications should be offered contraceptive methods in accordance with CDC, WHO, or other relevant national guidance. Mobile applications are readily available for quick reference regarding patients' eligibility for contraceptive methods based on concurrent use of anticonvulsants, antimicrobials, or antiretrovirals.

Obese patients – Obese patients (ie, body mass index ≥30 kg/m2) may have additional medical comorbidities or higher risk of venous thromboembolism that can impact their choice of postpartum contraception. Issues specific to obese patients who desire effective contraception, including method efficacy, are addressed elsewhere. (See "Contraception: Counseling for females with obesity".)

PATIENTS WHO ARE UNDECIDED ABOUT CONTRACEPTION — Patients who are undecided about contraception at any point during pregnancy or postpartum should be counseled regarding all of their options and given written support materials on contraceptive methods. Patients can be counseled on the effect on fertility of exclusive breastfeeding, as well as the risk of ovulation within the first four to six weeks postpartum. In addition, patients should be given comprehensive information on emergency contraception. Consistent with the American College of Obstetricians and Gynecologists, we believe that contact with a provider during the postpartum period should be a process rather than a discrete visit and should occur at least once in the one to three weeks postpartum, with individualization of ongoing follow-up as needed [2]. Thus, contraception can and should be addressed at more than one time point in the postpartum period if needed. However, patients should not be made to feel pressured to choose a method if they are undecided or would prefer behavioral methods of pregnancy prevention such as abstinence, withdrawal, lactational amenorrhea method, or fertility awareness methods. (See "Contraception: Counseling and selection".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Contraception" and "Society guideline links: Postpartum care".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Beyond the Basics topic (see "Patient education: Birth control; which method is right for me? (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Return of ovulation – In a systematic review of studies estimating the time to return to fertility in nonlactating postpartum participants, the average time to first ovulation varied from 45 to 94 days postpartum, with the earliest ovulation reported at 25 days postpartum. (See 'Resumption of ovulation' above.)

Contraceptive counseling points – For counseling people about contraception, we use a patient-centered, shared decision-making model. Key components to discuss include the patient's reproductive life plan, desired characteristics of contraceptives, medical issues or comorbidities, and plans for breastfeeding. (See 'Our approach to counseling' above.)

Patients who are undecided about contraception at any point during pregnancy or postpartum are counseled regarding all of their options and given written support materials on contraceptive methods, including emergency contraception. (See 'Emergency contraception' above and 'Patients who are undecided about contraception' above.)

Contraceptives for immediate postpartum use – Contraceptive methods that can be initiated immediately after delivery include female and male permanent contraception, progestin-only implants, intrauterine devices (IUD; copper or levonorgestrel), the progestin injection, and the progestin-only pill. (See 'Permanent contraception' above and 'Progestin-only implants' above and 'Intrauterine devices' above.)

Timing options for IUD insertion – For those who desire an IUD after delivery, explicit counseling should center on timing of IUD insertion. IUD insertion timing can be postplacental, delayed, or interval. Risks (eg, expulsion and perforation) and benefits (eg, effectiveness) vary by timing of IUD placement after delivery. (See 'Options for timing of insertion after delivery' above.)

Risks and benefits of postpartum IUD insertion – Issues that we discuss with patients who desire a postpartum intrauterine device include the risks of IUD expulsion, perforation of the uterus, and IUD malposition. Despite these concerns, the odds of using an IUD six months after delivery is twice as high for those who receive a postplacental IUD as compared with interval insertion. (See 'Issues related to postpartum IUD insertion' above.)

Delayed start of estrogen-containing contraceptives – For those who desire short-acting combined estrogen-progestin contraception, the oral pill, transdermal patch, and vaginal ring should not be started earlier than 21 days postpartum for anyone because of the increased risk of venous thromboembolism (VTE). (See 'Short-acting hormonal contraception' above.)

Impact of postpartum contraception  

Lactation – In general, the progestin-only methods appear to have minimal to no effect on breastfeeding outcomes. Studies assessing the impact of combined hormonal contraceptives (CHCs; pills, patch, vaginal ring) on breastfeeding duration and success have reported inconsistent data. The Centers for Disease Control and Prevention and the World Health Organization recommendations about hormonal contraceptives and breastfeeding differ. (See 'Issues surrounding hormonal contraception during breastfeeding' above.)

VTE risk – No studies have evaluated the incidence of VTE in postpartum patients using CHCs or progestin-only contraceptives. However, the risk of VTE associated with CHC use in healthy nonpregnant patients is three to seven times higher than in nonusers, and thus use of CHC for the initial three to six weeks postpartum is generally contraindicated. (See 'Counseling regarding venous thromboembolism risk and hormonal contraception in the postpartum period' above.)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges Andrew M. Kaunitz, MD, who contributed to an earlier version of this topic review.

  1. Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol 2011; 117:657.
  2. ACOG Committee Opinion No. 736: Optimizing Postpartum Care. Obstet Gynecol 2018; 131:e140. Reaffirmed 2021.
  3. Sonalkar S, Hunter T, Gurney EP, et al. A Decision Analysis Model of 1-Year Effectiveness of Intended Postplacental Compared With Intended Delayed Postpartum Intrauterine Device Insertion. Obstet Gynecol 2018; 132:1211.
  4. Byrd JE, Hyde JS, DeLamater JD, Plant EA. Sexuality during pregnancy and the year postpartum. J Fam Pract 1998; 47:305.
  5. Rogers RG, Borders N, Leeman LM, Albers LL. Does spontaneous genital tract trauma impact postpartum sexual function? J Midwifery Womens Health 2009; 54:98.
  6. Report of a WHO Technical Consultation on Birth Spacing. World Health Organization, Geneva, Switzerland, June 13-15, 2005.
  7. Ahrens KA, Nelson H, Stidd RL, et al. Short interpregnancy intervals and adverse perinatal outcomes in high-resource settings: An updated systematic review. Paediatr Perinat Epidemiol 2019; 33:O25.
  8. DaVanzo J, Hale L, Razzaque A, Rahman M. Effects of interpregnancy interval and outcome of the preceding pregnancy on pregnancy outcomes in Matlab, Bangladesh. BJOG 2007; 114:1079.
  9. DaVanzo J, Hale L, Razzaque A, Rahman M. The effects of pregnancy spacing on infant and child mortality in Matlab, Bangladesh: how they vary by the type of pregnancy outcome that began the interval. Popul Stud (Camb) 2008; 62:131.
  10. Cleland J, Shah IH, Benova L. A Fresh Look at the Level of Unmet Need for Family Planning in the Postpartum Period, Its Causes and Program Implications. Int Perspect Sex Reprod Health 2015; 41:155.
  11. Ross J, Winfrey W. Contraceptive Use, Intention to Use and Unmet Need During the Extended Postpartum Period. Int Fam Plann Persp 2001; 27:20.
  12. Rossier C, Bradley SE, Ross J, Winfrey W. Reassessing Unmet Need for Family Planning in the Postpartum Period. Stud Fam Plann 2015; 46:355.
  13. Brunson MR, Klein DA, Olsen CH, et al. Postpartum contraception: initiation and effectiveness in a large universal healthcare system. Am J Obstet Gynecol 2017.
  14. Damle LF, Gohari AC, McEvoy AK, et al. Early initiation of postpartum contraception: does it decrease rapid repeat pregnancy in adolescents? J Pediatr Adolesc Gynecol 2015; 28:57.
  15. Gifford K, McDuffie MJ, Rashid H, et al. Postpartum contraception method type and risk of a short interpregnancy interval in a state Medicaid population. Contraception 2021; 104:284.
  16. Steenland MW, Pace LE, Sinaiko AD, Cohen JL. Association Between South Carolina Medicaid's Change in Payment for Immediate Postpartum Long-Acting Reversible Contraception and Birth Intervals. JAMA 2019; 322:76.
  17. Steenland MW, Pace LE, Cohen JL. Association of Medicaid Reimbursement for Immediate Postpartum Long-acting Reversible Contraception With Infant Birth Outcomes. JAMA Pediatr 2022; 176:296.
  18. Thurman AR, Janecek T. One-year follow-up of women with unfulfilled postpartum sterilization requests. Obstet Gynecol 2010; 116:1071.
  19. Van der Wijden C, Manion C. Lactational amenorrhoea method for family planning. Cochrane Database Syst Rev 2015; :CD001329.
  20. Dehlendorf C, Grumbach K, Schmittdiel JA, Steinauer J. Shared decision making in contraceptive counseling. Contraception 2017; 95:452.
  21. Hapenney S. Divergent practices among Catholic hospitals in provision of direct sterilization. Linacre Q 2013; 80:32.
  22. Guiahi M, Sheeder J, Teal S. Are women aware of religious restrictions on reproductive health at Catholic hospitals? A survey of women's expectations and preferences for family planning care. Contraception 2014; 90:429.
  23. Envision Sexual and Reproductive Health. PATH questions. https://www.envisionsrh.com/path-questions-examples (Accessed on November 20, 2018).
  24. Teal SB, Sheeder J. Balancing the Risks and Desires for Pregnancy in Older Mothers: Increasing Morbidity, Declining Fertility. JAMA Intern Med 2018; 178:1671.
  25. Jackson AV, Karasek D, Dehlendorf C, Foster DG. Racial and ethnic differences in women's preferences for features of contraceptive methods. Contraception 2016; 93:406.
  26. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
  27. Medical Eligibility Criteria for Contraceptive Use, 5th ed, World Health Organization, Geneva 2015.
  28. Phillips SJ, Tepper NK, Kapp N, et al. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception 2016; 94:226.
  29. Tepper NK, Phillips SJ, Kapp N, et al. Combined hormonal contraceptive use among breastfeeding women: an updated systematic review. Contraception 2016; 94:262.
  30. Bryant AG, Lyerly AD, DeVane-Johnson S, et al. Hormonal contraception, breastfeeding and bedside advocacy: the case for patient-centered care. Contraception 2019; 99:73.
  31. Zite N, Wuellner S, Gilliam M. Failure to obtain desired postpartum sterilization: risk and predictors. Obstet Gynecol 2005; 105:794.
  32. Albanese A, French M, Gossett DR. Request and fulfillment of postpartum tubal ligation in patients after high-risk pregnancy. Contraception 2017; 95:234.
  33. Wolfe KK, Wilson MD, Hou MY, Creinin MD. An updated assessment of postpartum sterilization fulfillment after vaginal delivery. Contraception 2017; 96:41.
  34. Guiahi M, McNulty M, Garbe G, et al. Changing depot medroxyprogesterone acetate access at a faith-based institution. Contraception 2011; 84:280.
  35. Stern AM. Sterilized in the name of public health: race, immigration, and reproductive control in modern California. Am J Public Health 2005; 95:1128.
  36. Hevia M, Constantin A. Gendered Power Relations and Informed Consent: The I.V. v. Bolivia Case. Health Hum Rights 2018; 20:197.
  37. Reilly PR. Eugenics and Involuntary Sterilization: 1907-2015. Annu Rev Genomics Hum Genet 2015; 16:351.
  38. Kendall T, Albert C. Experiences of coercion to sterilize and forced sterilization among women living with HIV in Latin America. J Int AIDS Soc 2015; 18:19462.
  39. Atkinson HG, Ottenheimer D. Involuntary sterilization among HIV-positive Garifuna women from Honduras seeking asylum in the United States: Two case reports. J Forensic Leg Med 2018; 56:94.
  40. Borrero S, Zite N, Potter JE, Trussell J. Medicaid policy on sterilization--anachronistic or still relevant? N Engl J Med 2014; 370:102.
  41. Natavio MF, Cortessis VK, Zite NB, et al. The use of a low-literacy version of the Medicaid sterilization consent form to assess sterilization-related knowledge in Spanish-speaking women: results from a randomized controlled trial. Contraception 2018; 97:546.
  42. Whitaker AK, Chen BA. Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices. Contraception 2018; 97:2.
  43. Sonalkar S, Kapp N. Intrauterine device insertion in the postpartum period: a systematic review. Eur J Contracept Reprod Health Care 2015; 20:4.
  44. Lopez LM, Bernholc A, Hubacher D, et al. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database Syst Rev 2015; :CD003036.
  45. Caliskan E, Oztürk N, Dilbaz BO, Dilbaz S. Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur J Contracept Reprod Health Care 2003; 8:150.
  46. Chen BA, Reeves MF, Hayes JL, et al. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2010; 116:1079.
  47. Whitaker AK, Endres LK, Mistretta SQ, Gilliam ML. Postplacental insertion of the levonorgestrel intrauterine device after cesarean delivery vs. delayed insertion: a randomized controlled trial. Contraception 2014; 89:534.
  48. Lester F, Kakaire O, Byamugisha J, et al. Intracesarean insertion of the Copper T380A versus 6 weeks postcesarean: a randomized clinical trial. Contraception 2015; 91:198.
  49. Levi EE, Stuart GS, Zerden ML, et al. Intrauterine Device Placement During Cesarean Delivery and Continued Use 6 Months Postpartum: A Randomized Controlled Trial. Obstet Gynecol 2015; 126:5.
  50. Elsedeek MS. Puerperal and menstrual bleeding patterns with different types of contraceptive device fitted during elective cesarean delivery. Int J Gynaecol Obstet 2012; 116:31.
  51. Welkovic S, Costa LO, Faúndes A, et al. Post-partum bleeding and infection after post-placental IUD insertion. Contraception 2001; 63:155.
  52. Wilcox A, Levi EE, Garrett JM. Predictors of Non-Attendance to the Postpartum Follow-up Visit. Matern Child Health J 2016; 20:22.
  53. Chen MJ, Hsia JK, Hou MY, et al. Comparing Postpartum Visit Attendance with a Scheduled 2- to 3-Week or 6-Week Visit after Delivery. Am J Perinatol 2019; 36:936.
  54. Jatlaoui TC, Whiteman MK, Jeng G, et al. Intrauterine Device Expulsion After Postpartum Placement: A Systematic Review and Meta-analysis. Obstet Gynecol 2018; 132:895.
  55. Cohen R, Sheeder J, Arango N, et al. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices. Contraception 2016; 93:178.
  56. Chi IC, Wilkens L, Rogers S. Expulsions in immediate postpartum insertions of Lippes Loop D and Copper T IUDs and their counterpart Delta devices--an epidemiological analysis. Contraception 1985; 32:119.
  57. Stuart GS, Lesko CR, Stuebe AM, et al. A randomized trial of levonorgestrel intrauterine system insertion 6 to 48 h compared to 6 weeks after vaginal delivery; lessons learned. Contraception 2015; 91:284.
  58. Aoun J, Dines VA, Stovall DW, et al. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 2014; 123:585.
  59. Madden T, McNicholas C, Zhao Q, et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014; 124:718.
  60. Hinz EK, Murthy A, Wang B, et al. A prospective cohort study comparing expulsion after postplacental insertion: the levonorgestrel versus the copper intrauterine device. Contraception 2019; 100:101.
  61. Averbach SH, Ermias Y, Jeng G, et al. Expulsion of intrauterine devices after postpartum placement by timing of placement, delivery type, and intrauterine device type: a systematic review and meta-analysis. Am J Obstet Gynecol 2020; 223:177.
  62. Armstrong MA, Raine-Bennett T, Reed SD, et al. Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion. JAMA Netw Open 2022; 5:e2148474.
  63. Martinez OP, Wilder L, Seal P. Ultrasound-Guided Compared With Non-Ultrasound-Guided Placement of Immediate Postpartum Intrauterine Contraceptive Devices. Obstet Gynecol 2022; 140:91.
  64. Gurney EP, Sonalkar S, McAllister A, et al. Six-month expulsion of postplacental copper intrauterine devices placed after vaginal delivery. Am J Obstet Gynecol 2018; 219:183.e1.
  65. Ramos-Rivera M, Averbach S, Selvaduray P, et al. Complications after interval postpartum intrauterine device insertion. Am J Obstet Gynecol 2022; 226:95.e1.
  66. Baldwin MK, Edelman AB, Lim JY, et al. Intrauterine device placement at 3 versus 6 weeks postpartum: a randomized trial. Contraception 2016; 93:356.
  67. Anthony MS, Reed SD, Armstrong MA, et al. Design of the Association of Uterine Perforation and Expulsion of Intrauterine Device study: a multisite retrospective cohort study. Am J Obstet Gynecol 2021; 224:599.e1.
  68. Berry-Bibee EN, Tepper NK, Jatlaoui TC, et al. The safety of intrauterine devices in breastfeeding women: a systematic review. Contraception 2016; 94:725.
  69. Heinemann K, Barnett C, Reed S, et al. IUD use among parous women and risk of uterine perforation: a secondary analysis. Contraception 2017; 95:605.
  70. Rowe P, Farley T, Peregoudov A, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: A 7-year randomized comparative study with the TCu380A. Contraception 2016; 93:498.
  71. Braaten KP, Benson CB, Maurer R, Goldberg AB. Malpositioned intrauterine contraceptive devices: risk factors, outcomes, and future pregnancies. Obstet Gynecol 2011; 118:1014.
  72. Sivin I, Shaaban M, Odlind V, et al. A randomized trial of the Gyne T 380 and Gyne T 380 Slimline Intrauterine Copper devices. Contraception 1990; 42:379.
  73. Bahamondes L, Díaz J, Petta C, et al. Comparison of the performances of TCu380A and TCu380S IUDs up to five years. Adv Contracept 1999; 15:275.
  74. Blumenthal PD, Lerma K, Bhamrah R, et al. Comparative safety and efficacy of a dedicated postpartum IUD inserter versus forceps for immediate postpartum IUD insertion: a randomized trial. Contraception 2018; 98:215.
  75. Colwill AC, Schreiber CA, Sammel MD, Sonalkar S. Six-week retention after postplacental copper intrauterine device placement. Contraception 2018; 97:215.
  76. Singata-Madliki M, Hofmeyr GJ, Lawrie TA. The effect of depot medroxyprogesterone acetate on postnatal depression: a randomised controlled trial. J Fam Plann Reprod Health Care 2016; 42:171.
  77. Tsai R, Schaffir J. Effect of depot medroxyprogesterone acetate on postpartum depression. Contraception 2010; 82:174.
  78. Tepper NK, Jeng G, Curtis KM, et al. Venous Thromboembolism Among Women Initiating Depot Medroxyprogesterone Acetate Immediately Postpartum. Obstet Gynecol 2019; 133:533.
  79. Sackeim MG, Gurney EP, Koelper N, et al. Effect of contraceptive choice on rapid repeat pregnancy. Contraception 2019; 99:184.
  80. McNeilly AS, Tay CC, Glasier A. Physiological mechanisms underlying lactational amenorrhea. Ann N Y Acad Sci 1994; 709:145.
  81. Thomas MA, Chappell BT, Maximos B, et al. A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial. Contracept X 2020; 2:100031.
  82. Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
  83. Horta BL, Victora CG. Short-term effects of breastfeeding: A systematic review on the benefits of breastfeeding on diarrhoea and pneumonia mortality. World Health Organization http://apps.who.int/iris/bitstream/handle/10665/95585/9789241506120_eng.pdf?sequence=1 (Accessed on January 07, 2019).
  84. Stanton TA, Blumenthal PD. Postpartum hormonal contraception in breastfeeding women. Curr Opin Obstet Gynecol 2019; 31:441.
  85. Henkel A, Lerma K, Reyes G, et al. Lactogenesis and breastfeeding after immediate versus delayed birth-hospitalization insertion of etonogestrel contraceptive implant: A non-inferiority trial. Am J Obstet Gynecol 2022.
  86. Braga GC, Ferriolli E, Quintana SM, et al. Immediate postpartum initiation of etonogestrel-releasing implant: A randomized controlled trial on breastfeeding impact. Contraception 2015; 92:536.
  87. Averbach S, Kakaire O, McDiehl R, et al. The effect of immediate postpartum levonorgestrel contraceptive implant use on breastfeeding and infant growth: a randomized controlled trial. Contraception 2019; 99:87.
  88. Turok DK, Leeman L, Sanders JN, et al. Immediate postpartum levonorgestrel intrauterine device insertion and breast-feeding outcomes: a noninferiority randomized controlled trial. Am J Obstet Gynecol 2017; 217:665.e1.
  89. Giner Velázquez J, Cortés Gallegos V, Sotelo López A, Bondani G. [Effect of daily oral administration of 0.350 mg of norethindrone on lactation and on the composition of milk]. Ginecol Obstet Mex 1976; 40:31.
  90. Espey E, Ogburn T, Leeman L, et al. Effect of progestin compared with combined oral contraceptive pills on lactation: a randomized controlled trial. Obstet Gynecol 2012; 119:5.
  91. Lopez LM, Grey TW, Stuebe AM, et al. Combined hormonal versus nonhormonal versus progestin-only contraception in lactation. Cochrane Database Syst Rev 2015; :CD003988.
  92. Bahamondes L, Bahamondes MV, Modesto W, et al. Effect of hormonal contraceptives during breastfeeding on infant's milk ingestion and growth. Fertil Steril 2013; 100:445.
  93. Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol 2011; 117:691.
  94. Floyd JL, Beasley AD, Swaim LS, et al. Association of Immediate Postpartum Etonogestrel Implant Insertion and Venous Thromboembolism. Obstet Gynecol 2020; 135:1275.
  95. Bergendal A, Persson I, Odeberg J, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014; 124:600.
  96. van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30:2297.
  97. Worly BL, Gur TL, Schaffir J. The relationship between progestin hormonal contraception and depression: a systematic review. Contraception 2018; 97:478.
  98. Lawrie TA, Hofmeyr GJ, De Jager M, et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol 1998; 105:1082.
Topic 6708 Version 108.0

References